BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33719003)

  • 61. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
    Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
    Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study.
    Stemann Lau T; Dam G; Jepsen P; Grønbæk H; Krogh K; Gregersen T
    Neuroendocrinology; 2018; 107(3):280-283. PubMed ID: 30092588
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pathology - grading and staging of GEP-NETs.
    Capelli P; Fassan M; Scarpa A
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
    [TBL] [Abstract][Full Text] [Related]  

  • 69. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.
    Fermi F; Andreasi V; Muffatti F; Crippa S; Tamburrino D; Partelli S; Falconi M
    Curr Oncol Rep; 2022 Feb; 24(2):227-239. PubMed ID: 35076884
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
    Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
    Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GEP-NET radiomics: a systematic review and radiomics quality score assessment.
    Staal FCR; Aalbersberg EA; van der Velden D; Wilthagen EA; Tesselaar MET; Beets-Tan RGH; Maas M
    Eur Radiol; 2022 Oct; 32(10):7278-7294. PubMed ID: 35882634
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL; Mosquera C; Lea CS; McMullen M
    Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
    Niederle MB; Hackl M; Kaserer K; Niederle B
    Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
    Koch C; Koca E; Filmann N; Husmann G; Bojunga J
    Medicine (Baltimore); 2021 Sep; 100(37):e27276. PubMed ID: 34664885
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
    Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
    Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
    [No Abstract]   [Full Text] [Related]  

  • 78. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms in Krakow and Krakow district in 2007-2011.
    Trofimiuk-Müldner M; Lewkowicz E; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2017; 68(1):42-46. PubMed ID: 28255979
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
    Garcia-Carbonero R
    Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.